|
|
While drug, device, and drug/device combination trials share many similarities, they also differ in many ways. From increasing and currently evolving regulatory differences, to organization of the study team running the device trials, having experience with device studies is critical to ensuring long-term success, as well as, decreasing cost and time when implementing EDC. OmniComm has that experience, and it spans many therapeutic areas. Furthermore, while industry-standards for data currently remain comparable across drug and device studies, OmniComm continues to monitor and plan for upcoming changes in these standards and make provisions within our software to accommodate pending new standards. If you would like to learn more, please contact Bev Hudson bhudson@omnicomm.com |